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Abstract
We report a first method for using M13 bacteriophage as a multifunctional scaffold for optically
imaging bacterial infections in vivo. We demonstrate that M13 virus conjugated with hundreds of
dye molecules (M13-Dye) can target and distinguish pathogenic infections of F-pili expressing
and F-negative strains of E. coli. Further, in order to tune this M13-Dye complex suitable for
targeting other strains of bacteria, we have used a 1-step reaction for creating an anti-bacterial
antibody-M13-Dye probe. As an example, we show anti-S.aureus-M13-Dye able to target and
image infections of S. aureus in living hosts, with a 3.7x increase in fluorescence over
background.
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The ability to image and noninvasively monitor bacterial infections in tissue has been a
challenging area in the field of pathology. The increasing development of bacterial
resistance to antibiotics has reached high proportions, and thus there is a need for imaging
tools to facilitate early detection and treatment of bacterial infections. In the US alone, the
economic impact of antibiotic-resistant bacterial infections is estimated ~$5-$24 billion per
year [1].
Optical imaging of bacteria in vivo is much less developed than other methods such as
radioimaging [2], [3]; due to lack of availability of target-specific molecular probes. One
early approach was using genetic reporter systems such as light-emitting luciferase enzymes
[4], or green fluorescent protein (GFP). Although this has proved to be an important tool for
visualizing bacteria, these reporters are not endogenously expressed in most pathogens.
Therefore, there is a need for developing bacterial targeting probes with exogenous contrast
agents for optical imaging.
Several studies have employed antibodies, lectins, sugars, antibiotic drugs, enzyme
substrates and antimicrobial peptides [5],[6], cell-wall penetrating cationic peptides [7],[8]
and specifically constructed compounds [9],[10],[11] as affinity ligands for targeting
bacteria. While these are promising candidates for imaging bacterial infections, there are
still doubts concerning the specificity of some of these probes, due to the possibility of the
ligand targeting the adjacent necrotic tissue produced by the infection [9]. In contrast, probes
based on antibody-mediated targeting are a popular choice because they can bind tightly to
specific molecular targets on the surfaces of both Gram-positive and Gram-negative
bacteria.
M13 bacteriophage is an attractive candidate for targeting bacterial infections, because of its
natural binding affinity to bacteria which express F-pili, and its five capsid proteins which
can be genetically engineered to display targeting motifs against tumor cells [12],[13], drug
molecules or fluorescent dyes [14] for strain-specific detection and imaging of bacteria.
Although M13 has been used for detection of tumors [13],[15], gene delivery methods for
phage therapy [16],[17],[18] and in antibiotic therapy [19] for treating bacterial infections in
survival studies, there has been no reported application of M13 used as a targeted in vivo
imaging probe for infectious diseases, to the best of our knowledge. In this work, we
describe a first approach to using M13 as a multifunctional scaffold, fluorescently labeled
with dye molecules, for targeting and imaging bacterial infections.
2. Experimental
2.1 Labeling of Fluorescent Dye on M13 phage
M13 virus was suspended at a concentration of 3×1013 pfu/mL (plaque forming units per
mL) in 1x phosphate buffered saline (PBS). Alexa Fluor 750 dye was used (Life
Technologies, NY, USA), with an absorbance maximum at 749nm, and emission maximum
at 775nm. After reacting the dye with M13 for 2hr in dark, the solution was dialyzed
extensively against 1x PBS for 48hr, to remove unreacted dye molecules. After dialysis, the
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M13-Dye complex was precipitated by adding high ionic strength salt solution of PEG-NaCl
(2M) at 4°C, and centrifuged at 15,000rpm for 10min. The supernatant was discarded to get
rid of unreacted dye molecules, and the M13-dye pellet was resuspended in 1x PBS. After 3
such steps, absorption spectra were taken with a DU-800 Spectrophotometer (Beckman
Coulter, CA, USA).
2.2 Cell Lines and Culture
E. coli of two strains, DH5-α (New England Biolabs, MA, USA) and JM109 (Promega, WI,
USA) were used, of which the former lacks F-pili, the latter is F-pilus positive. We used
Xen-29 strain of Staphylococcus aureus, and Xen-05 strain of Pseudomonas aeruginosa
(Caliper Life Sciences, MA, USA). All bacteria were grown in LB broth, with 50 μg/mL
tetracycline for the E. coli and P. aeruginosa strains, and 50 μg/mL kanamycin for S.
aureus. The bacteria were grown in an incubator at 37°C under vigorous shaking at 250rpm,
till O.D.600 absorbance attained a value of 0.5.
2.3 In vitro Binding Assay
Bacterial strains were grown to a density of 108 cfu/mL (colony forming units per mL) in
LB media. 100μL of this culture was added per well, of a 96-well plate. Depending on the
strain of bacteria, we added our probe (M13-Dye for the E. coli strains JM109 or DH5-α,
and anti-S.aureus-M13-Dye for the S. aureus strain Xen-29). As negative controls, we used
free dye in PBS. The probe was incubated with the bacteria for 1hr. in the culture medium.
After 1hr., we centrifuged the plate to sediment the bacteria. The unbound bacteria and
unattached probe were removed by 3 PBS wash steps. Finally the cells were resuspended in
100μL PBS. Fluorescence images were taken on a Xenogen IVIS imaging instrument
(Caliper Life Sciences, MA, USA).
2.4 1-step Tunability of M13 Phage
In order to enable the M13 phage to selectively conjugate to other strains of bacteria which
do not natively have F-pili, we used a 1-step tuning process. Previously [15], a method has
been reported to express biotin acceptor peptide (BAP), GLNDIFEAQKIEWHE [20], on the
p3 coat protein of the M13 bacteriophage. M13 viruses expressing BAP (BAP-M13) were
then enzymatically biotinylated at the lysine residue (Lys10) using a biotin-protein ligase
(Avidity, CO, USA). Antibodies against bacteria were complexed to streptavidin using a
commercially available kit (EasyLink Streptavidin kit, abcam, Cambridge, MA). This
complex was then reacted with biotinylated BAP-M13 to develop probes (antibacterial
antibody-M13-Dye) for targeting against specific bacterial infections.
2.5 Mouse Handling and Fluorescence Whole-Animal Imaging
All animal handling procedures were done in accordance with Institutional Animal Care and
Use Committee protocols. Animal procedures were pre-approved by the Massachusetts
Institute of Technology's Committee on Animal Care.
For infection studies, 43-56 days old female nude nu/nu mice were used (strain 088, Charles
River Laboratories, MA, USA). Two sets of experiments were performed, involving E. coli
and S. aureus strains. For each strain, two groups of N=5 mice were studied. In the first set,
Bardhan et al. Page 3













one group received the DH5-α strain, and the second group received JM109. In the second
set, all mice received the Xen-29 strain. 108 cells of bacteria in 50μL LB media were
injected in the right caudal thigh muscle using a 25 gauge needle. As a control, 50μL of 1x
PBS was also injected in the left thigh. As a second negative control test for our probe
specificity, 5×107 cells of P. aeruginosa were injected in N=5 mice. For the mice injected
with S. aureus or P. aeruginosa, the bacterial infection was visualized by bioluminescence
imaging (IVIS Spectrum, Caliper Life Sciences, MA, USA). After incubating the bacteria in
the living host for 1hr., 200μL of the M13-Dye probe (or anti-S.aureus-M13-Dye for the
positive control group of the S. aureus set and the negative control P. aeruginosa set) was
injected into the circulation through a retro-orbital injection. The time of injection of the
M13-Dye probe was taken as t = 0. Post injection, mice were imaged at t = 1hr, 2, 4, 8, 12
and 24hr. on the IVIS instrument, using a 745nm excitation and an 800nm fluorescence
emission filter.
Post this imaging sequence, mice were euthanized by CO2 inhalation. We collected muscle
tissue from the right flank (site of bacterial infection) and left flank (negative control PBS
injection). Fluorescence images of as-excised tissues were taken on the IVIS instrument.
After imaging, the excised tissues were fixed in 10% formalin and mounted in paraffin wax.
2.6 Microscopy Analysis
5μm tissue sections were mounted on glass slides and stained with Gram staining kit
(Sigma-Aldrich, St. Louis, MO). They were imaged with a Zeiss Axioplan II upright
microscope with objective lenses of 25x and 100x magnification, under oil-immersion.
3. Results and discussion
M13 is a long, cylindrical filamentous non-lytic bacteriophage. Figure 1a shows the typical
structure of M13 loaded with near-infrared dye molecules attached to the p8 coat protein
(M13-Dye). Figure 1b shows absorbance spectrum measured to quantify the labeling of dye
molecules on the M13 phage. From the absorption value at λ = 269nm, compared to a
320nm reference [21], the phage concentration was determined to be 3×1013 pfu/mL. The
Alexa Fluor 750 dye has an absorption maximum at λmax = 749nm, with an extinction
coefficient ε = 240,000 cm–1M–1. We measure an absorbance value A = 1.76, for a path
length l = 1cm. Using the Beer-Lambert law A = εlc, we calculate the concentration of the
dye to be c = 7.33μM, or equivalently, 4.42×1015 dye molecules per mL. Therefore, the
average number of dye molecules per phage works out to be ~150. This ability to conjugate
hundreds of dye molecules through high avidity binding on a single carrier vector (M13) for
targeting and signal amplification at the site of bacterial infection is one of the key
advantages of our M13-Dye system, similar to effects observed when using M13 for
delivering magnetic nanoparticles for imaging [22]. Following the M13-Dye conjugation
reaction, the product was dialyzed extensively and followed with several rounds of
precipitation to remove excess, unreacted dye molecules. Inset to Figure 1b shows the clear
supernatant after precipitating the blue pellet of M13-Dye, indicated by the yellow arrow.
There is very little residual absorption measured in the supernatant, indicating that there is
no unbound dye detectable. Figure 2 shows the results of our plate assay to determine the
binding affinity of our M13-Dye complex to different strains of bacteria. For the E. coli
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strains, from Figure 2a it is observed that M13-Dye binds specifically to the F-positive
JM109, with a 2.3x increase in fluorescence intensity over the F-negative DH5-α strain.
There is slight nonspecific binding in the latter, which has a higher fluorescence intensity
compared to the background intensity of free dye in PBS (control).
Further, we have conjugated an antibody against S. aureus on the M13-Dye probe (anti-
S.aureus-M13-Dye). Figure 2b shows the results of our in vitro binding assay. We observe a
3.3x increase in binding to S. aureus by the antibody-conjugated anti-S.aureus-M13-Dye
complex, over the M13-Dye alone. The latter has a slight non-specific binding to S. aureus,
~1.5x compared to free dye in PBS (control).
This ability to modulate the binding affinity of our M13-Dye complex simply by adding a
suitable antibody on the p3 is another key advantage, which makes our probe versatile for
detecting a wide range of infectious pathogens.
Based on the outcome of our in vitro plate assay, we tested the ability of our M13-Dye
conjugate to target and locate the site of bacterial infection in living hosts. In order to
determine the optimum time for fluorescence intensity comparison, we first performed a
study of the time-course of circulation and uptake of our M13-Dye probe. Figure 3 shows a
subset of the results of our time-course imaging. At t = 0 post injection (p.i.), we observe
diffuse fluorescence throughout the whole body, as the probe is under circulation. Specific
organs such as the liver and spleen are also visible in some cases. With time, the probe starts
clearing from circulation, and accumulation is observed at the site of infection. The peak
accumulation is observed to occur around t = 8hr. for the S. aureus infections, and t = 24hr.
for the E. coli infections, shown in Figure 3. Beyond this peak signal, the fluorescence
intensity starts decreasing, although the infection site is still distinguishable at later times.
We propose that the optimal wait times for targeted imaging are 24hr. and 8hr., for the E.
coli infections and S. aureus infections respectively.
We compared the fluorescence signal intensity of our M13-Dye probe, for targeted and non-
targeted cases, and measured the increase in fluorescence compared to PBS injections in the
left flank (control). These measurements were performed at the time of peak intensity, i.e. at
t = 8hr. for the S. aureus injections, and t = 24hr. for the E. coli injections and the negative
control P. aeruginosa injections. Region of interest (ROI) analysis was performed on these
groups, to determine the Target/PBS and Non-Target/PBS fluorescence ratios, as shown in
Figure 4a. Also shown are the bioluminescence images of the Xen-29 bacteria, showing
colocalization of the probe accumulation at the site of bacterial infection.
Figure 4b shows the results of our ROI analyses. We discuss the positive controls first
(JM109 v. M13-Dye and Xen-29 v. anti-S.aureus-M13-Dye). For the E. coli strain JM109,
which is F-positive, we observe a 2.7x increase in intensity compared to control PBS. For
the S. aureus strain Xen-29, targeted using an anti-S.aureus antibody conjugated to the M13-
Dye, we observe a stronger enhancement ~3.7x compared to PBS control. Both the non-
targeted negative controls (DH5-α v. M13-Dye and Xen-29 v. M13-Dye) show a 1.3-1.5x
increase in intensity over PBS control, which suggests minor non-specific binding of our
probe. These results compare to similar ratios of targeting observed in our in vitro assays,
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shown in Figure 2. To assess the specificity of our anti-S.aureus-M13-Dye probe, we
injected it into mice infected with P. aeruginosa. We observe a fluorescence enhancement of
~1.2x over PBS control, which is comparable to the other negative control cases discussed
above. It may be observed that the increases in fluorescence intensity for the targeted cases
are slightly lower for whole-animal imaging compared to plate assays. This may be
attributed to the slower rate of targeting through circulation. We observe an enhancement
factor closer to the in vitro results upon excising the tissue, as shown in Figure 5.
In order to further verify the uptake of our M13-Dye probe and eliminate false positives, we
sacrificed the animals after t = 24hr. Tissue samples from both the right flank (site of
infection) and the left flank (PBS control) were excised and fluorescence images were taken.
Figure 5a shows the ROI analysis performed (blue outlines). Columns 1 and 3 of the plate
correspond to PBS-injected tissues, while 2 and 4 are the targeted infection samples. We
observe a 4.1x increase in fluorescence intensity in the targeted tissues, compared to tissues
receiving control PBS injections. This compares favorably with our ROI analysis of whole-
animal images in Figure 4b, which yielded a 3.7x increase. This enhancement factor is
closer to the 4.9x increase observed for anti-S.aureus-M13-Dye in the plate assay results of
Figure 2b.
Further, these tissue samples were sectioned and stained for Gram-positive bacteria, shown
in Figure 5b. For the left muscle, we observe no evidence of staining. For the right flank
muscle tissues, we see presence of clusters of spherical cocci of S. aureus stained dark
violet, interspersed throughout the muscle tissue fibers. At 100x magnification, individual
cells of S. aureus are resolved, with sizes ranging from 0.5-0.8μm, similar to images
reported in literature [23]. The two observations of Figure 5a and 5b, combined together
with the whole-animal images of Figure 4, help us validate the targeting capability of our
anti-S.aureus-M13-Dye probe towards in vivo infections of S. aureus.
4. Conclusion
In this study, we have demonstrated a multifunctional, targeted, highly tunable composite
material, using M13 bacteriophage as a carrier vector, labeled with fluorescent dye
molecules (M13-Dye), for detecting and imaging pathogenic infections in living hosts. The
ability to attach hundreds of dye molecules onto a single carrier vector is one of the key
advantages of our system. We have shown the ability to distinguish infections in vivo,
between strains of E. coli which express F-pili appendages (such as JM109), from F-
negative ones (like DH5-α), with a 2.7x increase in fluorescence intensity over negative
control PBS injections.
Further, we have developed a 1-step process to enable the M13 virus to selectively attach to
strains of bacteria which do not express F-pili. Using an anti-S.aureus-M13-Dye probe, we
have shown the ability to selectively localize and target infections of S. aureus in vivo, with
a fluorescence signal ~3.7x higher than that of control PBS injections, and a 2.5x increase
over non-targeted M13-Dye. These results are corroborated through the analyses of
integrated fluorescence intensity observed in the excised tissue. This ability to tune the
Bardhan et al. Page 6













targeting motif of the M13 carrier through a simple 1-step antibody modification is one of
the key advantages of our M13-Dye probe system.
This work may potentially be extended in the future by engineering the M13 virus to attach
single-wall carbon nanotubes as an imaging probe for second-window near-infrared imaging
[15] for visualization of deeper infections in tissue, include delivery of antibiotics, gene
delivery, or phage therapy, for a complete diagnostics and therapy package solution.
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(a) Schematic structure of the M13 bacteriophage, rendered in green. Typical dimensions are
~880 nm in length and ~6 nm in diameter. The major coat protein p8 binds to several
hundred dye molecules, shown in red. At one end is the minor coat protein, p3, which can be
used to conjugate targeting ligands such as antibodies. (b) Absorbance spectra of M13-Dye
(blue curve). Inset shows the M13-Dye solution (left, blue liquid), and the clear supernatant
after precipitation thrice with PEG-NaCl (right, yellow arrow indicates phage pellet). There
is negligible residual absorption from the supernatant (green curve), indicating no unbound
free dye detected.
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Plate assay quantifying the binding affinity of M13-Dye probe to different strains of
bacteria. Each data point is the mean ±s.d. for n=6 wells. (a) M13-Dye binds to E. coli strain
JM109, which is F-positive, with a 2.3x increase in fluorescence intensity over F-negative
DH5-α. (b) anti-S.aureus-M13-Dye binds strongly to S. aureus strain Xen-29, with a 3.3x
increase compared to the non-targeted M13-Dye.
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Optical clearance profile of circulation and uptake of the M13-Dye probe, for the positive
control samples. One representative mouse is shown out of a cohort of N=5 samples for each
set. (a) For the E. coli strains, maximum uptake at the site of infection is observed at t =
24hr. post injection (p.i.). (b) For the S. aureus strain, maximum uptake is at t = 8hr. p.i. All
samples are normalized to the same range. The radiant efficiency scale reads 2E7-2E9
(photons/sec/cm2/sr)/(μW/cm2). (c) Fluorescence intensity at site of infection, normalized to
peak uptake, with time p.i.
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Specificity of uptake of the M13-Dye probe. (a) One representative mouse from each group
of N=5 mice injected with S. aureus is shown here. (top) Bioluminescent image from
Xen-29 bacteria. (bottom) Fluorescence of the M13-Dye based probe. The left panel mouse
is a non-targeted case (M13-Dye injection), while on the right is a targeted case (anti-
S.aureus-M13-Dye). The bioluminescence scale reads from 1000-5000 (Counts). The
fluorescence scale is 2E7-2E9 (photons/sec/cm2/sr)/(μW/cm2). ROI analysis was performed,
indicated by the blue circles, with a threshold set at 25% of maximum intensity. For
comparison, ROIs were taken to be of equal area, between target and non-target groups.
Similar analysis was performed with the mice injected with strains of E. coli (not shown
here). (b) Fluorescence signal (right flank) intensity enhancement, normalized to baseline
intensity (control PBS injections in left flank) plotted as mean ±s.d. of N=5 measurements.
#, ##: Student's t-test for paired data with one-tailed distribution.
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(a) Representative ROI analysis of excised muscle tissue for the positive control group (anti-
S.aureus-M13-Dye). One mouse was not injected with the probe. Because of the uneven
sizes of the excised tissue, an auto contour mapping function was used to determine the
ROIs (blue outlines). (b) Tissue sections with Gram staining, 25x objective, oil-immersion
lens. The scale bar is 15μm. (left) Muscle tissue taken from left flank (PBS control), (right)
muscle tissue from the right flank (bacterial injection). Inset shows part of the same sample
at 100x objective (scale bar is 3μm).
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